Withdrawals due to adverse events · Patients with active mild to moderate ulcerative colitis
Once daily dosing showed no clear difference in withdrawal due to adverse events compared with conventional dosing (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · Patients with active mild to moderate ulcerative colitis
Oral 5‐ASA showed no clear difference in withdrawal due to adverse events compared with comparator 5‐ASA (moderate certainty).
1 finding from 1 review
Withdrawals due to adverse events · Patients with active mild to moderate ulcerative colitis
Oral 5‐ASA probably leads to lower withdrawal due to adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Withdrawals due to adverse events · people with moderate to severe Crohn's disease in remission
Ustekinumab showed no clear difference in withdrawal due to adverse events compared with placebo (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · adults aged 18‐59 years with primary hypertension (mild to moderate systolic or diastolic hypertension)
It is very uncertain whether antihypertensive drug therapy changes withdrawal due to adverse events compared with control (very low certainty).
1 finding from 1 review
All‐cause serious adverse events · chronic obstructive pulmonary disease (COPD). Participants in included studies had an average baseline FEV1 of around 40% predicted and…
Tiotropium leads to lower all‐cause serious adverse events compared with ipratropium (high certainty).
1 finding from 1 review
Withdrawals due to adverse events · Patients with active mild to moderate ulcerative colitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Serious adverse events at longest · hospitalised adults with COVID‐19 (moderate to severe disease)
The intervention showed no clear difference in serious adverse events at longest (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · people with moderate to severe Crohn's disease in remission
Briakinumab showed no clear difference in withdrawals due to adverse events compared with placebo (low certainty).
1 finding from 1 review
Serious adverse events (by day 28) · individuals with moderate or severe COVID‐19
RBD‐specific polyclonal F(ab') 2 fragments of equine antibodies… showed no clear difference in serious adverse events (by day 28) compared with saline placebo (low certainty).
1 finding from 1 review
Vomiting · people with moderate to severe cancer pain
It is very uncertain whether hydromorphone changes specific adverse events – vomiting compared with morphine (very low certainty).
1 finding from 1 review
Vomiting · people with moderate to severe cancer pain
The review found no eligible studies for this question.
1 finding from 1 review
Vomiting · people with moderate to severe cancer pain
It is very uncertain whether hydromorphone changes specific adverse events – vomiting compared with oxycodone (very low certainty).
1 finding from 1 review
Dizziness · people with moderate to severe cancer pain
It is very uncertain whether hydromorphone changes specific adverse events – dizziness compared with morphine (very low certainty).
1 finding from 1 review
Dizziness · people with moderate to severe cancer pain
The review found no eligible studies for this question.
1 finding from 1 review
Dizziness · people with moderate to severe cancer pain
It is very uncertain whether hydromorphone changes specific adverse events – dizziness compared with oxycodone (very low certainty).
1 finding from 1 review
Adverse events ‐ treatment emergent · Adult patients aged >=18 years, clinically or radiographically diagnosed with TMD (McNeill 1997 criteria); moderate to severe pain of…
1 finding from 1 review
Tchivileva et al 2010: at least one treatment-emergent adverse event was reported by five participants (12.5%) during the propranolol period (nausea, diarrhoea, insomnia, dizziness, fatigue) and four participants (10%)…
1 study · 40 participants
GRADE not reported
Intervention not reported
Number of people with adverse events · people with dementia and mild to moderate pain
1 finding from 1 review
Serious adverse events ‐ not reported · individuals with moderate to severe disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Adverse events during study treatment · hospitalised adults with COVID‐19 (moderate to severe disease)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found